Diagnosing Dx

Elevra Consulting
  • 0.0（0則評分）
  • 生命科學
  • 每週更新

How do we transform cutting-edge scientific discoveries into life-saving diagnostics? On Diagnosing Dx, we explore the scientific innovation driving diagnostics forward, unpack industry challenges, and spotlight success stories. Join us as we speak with leading researchers and innovators at the forefront of Dx. Learn to: 🔹 Navigate industry challenges 🔹 Understand emerging science 🔹 Strategise for growth 🔹 Gain future-focused insight Essential listening for everyone involved in bringing new sciences to life in the Dx and Omics industry, Subscribe now!

  1. 3 天前

    Could a $127M Seed Round Change Women's Health Forever? - Dean Remy, Co-Founder @ Mativa Dx

    In this episode of Diagnosing Dx, David Filby is joined by Dean Remy, Co-Founder and Chief Commercial Officer at Mativa Diagnostics. Dean brings 35 years of experience across diagnostics, biotechnology, and therapeutics. He explains why pregnancy testing has barely changed in 50 years and how the traditional positive-or-negative result can leave women without critical information during the earliest weeks of pregnancy. Mativa is developing a reusable handheld device combining multiplex biomarker testing, graphene nanosensor technology, an AI-enabled app, and immediate care navigation. The company is also building a large longitudinal maternal biorepository to support future diagnostics, biomarker discovery, and therapeutic development. This is a practical conversation about maternal health innovation, consumer access, partnerships, regulation, data, and building a platform designed to support women throughout the pregnancy journey. Key takeaways: 🔹 Why the traditional pregnancy test does not provide women with enough early information 🔹 How Mativa plans to identify risks such as ectopic pregnancy and pre-eclampsia 🔹 Why a longitudinal maternal biorepository could transform diagnostics and therapeutic development 🔹 How retail, healthcare, pharmaceutical, and diagnostic partnerships could accelerate adoption 🔹 Why supporting the complete patient journey could define the next generation of diagnostics Chapters: 01:08 Introduction and Dean Remy’s background 03:24 Why maternal health urgently needs innovation 06:28 Mativa’s approach and the technology behind the platform 11:42 Building a comprehensive maternal biorepository 14:24 Commercial strategy and market positioning 17:13 Regulatory and reimbursement pathways 20:18 Capital raising and strategic partnerships 25:34 The future of Mativa and maternal diagnostics Guest: Dean Remy Co-Founder and Chief Commercial Officer at Mativa Diagnostics LinkedIn: https://www.linkedin.com/in/scisourceremy/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    Could a $127M Seed Round Change Women's Health Forever? - Dean Remy, Co-Founder @ Mativa Dx

  2. 7月28日

    Red Drop’s Bet on Pain-Free Blood Collection and the Next Wave of Diagnostics

    In this episode of Diagnosing Dx, David Filby is joined by Thomas Briggs, Chief Growth Officer at RedDrop Dx. Thomas brings more than 25 years of diagnostics and healthcare growth experience, spanning pharma, big diagnostics, medtech, and startup environments. In this conversation, we explore one of the most overlooked parts of diagnostics: blood collection, and why the process still looks far too similar to what it did decades ago. Thomas breaks down where arm-based micro-sampling could genuinely change patient experience, from paediatrics and neurodivergent patients to home testing, clinical trials, and difficult vein access. We also get into the commercial reality behind a product like this: where the most promising markets are, why education still matters, how labs and platforms need to adapt, and what it takes to build a medtech business without following the usual VC-heavy playbook. This is a practical conversation about workflow, access, patient experience, and what happens when a simple shift in blood collection could unlock broader changes across diagnostics and healthcare delivery. Key takeaways: 🔹 Why blood collection remains one of the least-innovated parts of diagnostics 🔹 Where arm-based micro-sampling could have the biggest clinical and commercial impact 🔹 Why paediatrics, neurodivergent patients, and difficult vein access are such important use cases 🔹 How home sampling could change clinical trials, routine monitoring, and direct-to-consumer care 🔹 What it takes to commercialise a medtech product in both consumer and managed-care settings Chapters: 01:51 Thomas Briggs’ background in diagnostics, pharma, and medtech 06:28 Moving from big corporates into startups 11:04 What RedDrop Dx is building and how the device works 14:39 Where the biggest commercial opportunities are for arm-based micro-sampling 18:48 Why education and awareness are still a major challenge 21:22 RedDrop Dx’s story so far and why it was bootstrapped 26:05 How the company is building for growth across different market segments 30:10 Future milestones, home collection clearance, and expansion into Europe 31:31 Thomas’s outlook on diagnostics, home testing, and micro-sampling in 2026 Guest: Thomas Briggs Chief Growth Officer at RedDrop Dx LinkedIn: https://www.linkedin.com/in/thomas-briggs-959865177/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    Red Drop’s Bet on Pain-Free Blood Collection and the Next Wave of Diagnostics

  3. 7月21日

    Why Cancer Patients Still Die From Infections We Can't Diagnose - Karius

    In this episode of Diagnosing Dx, David Filby is joined by Alec Ford, Chief Executive Officer at Karius. Alec brings decades of leadership experience across therapeutics, vaccines, and genomics. In this conversation, we explore how Karius is bringing genomics into infectious disease and why the company has focused so sharply on immunocompromised patients. The scale of the unmet need is staggering. Alec explains that 52% of cancer deaths in the US are due to infection rather than the underlying malignancy, rising to more than 60% in hematologic malignancies. He also shares that there are around 4 million hospital admissions for infection among cancer patients in the US each year, yet the standard hospital workup can still fail to identify the cause in far too many cases. We also discuss the company’s growth, physician adoption, and why outpatient infectious disease testing could become a major next step. This is a practical conversation about infectious disease diagnostics, commercialization, and building in one of the most important unmet areas in healthcare. Key takeaways: 🔹 Why infectious disease remains one of the biggest threats to immunocompromised patients 🔹 How Karius is using microbial cell-free DNA to diagnose infection from a simple blood draw 🔹 Why focus and disciplined market selection have been central to Karius’ growth 🔹 How physician confidence and education shape adoption of new diagnostics 🔹 Why outpatient infectious disease testing could become a major next step for the field Chapters: 01:00 Introduction and Alec Ford’s background 04:20 Transition from therapeutics to genomics 08:34 The founding story of Karius and how the technology works 14:52 Why Karius focused on immunocompromised patients 19:41 Scaling the company and driving adoption 27:20 Reimbursement, capital strategy, and path to profitability 34:40 The outpatient opportunity and Karius’ next chapter 45:03 Alec’s view on the diagnostics industry and what needs to change Guest: Alec Ford Chief Executive Officer at Karius LinkedIn: https://www.linkedin.com/in/alec-ford-b578003/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ Learn more about Karius here: https://kariusdx.com/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    Why Cancer Patients Still Die From Infections We Can't Diagnose - Karius

  4. 7月15日

    Can AI Rescue Cancer Drugs That Clinical Trials Say Have Failed?

    In this episode of Diagnosing Dx, David Filby is joined by Alexander Bagaev, Chief Product Officer at BostonGene. Alexander has spent more than a decade helping build BostonGene from an early-stage team into a global precision medicine company. In this conversation, we explore why oncology is moving beyond single biomarkers and how BostonGene has expanded from diagnostics into AI-powered treatment selection and clinical trial support. We also discuss the challenge of bringing more comprehensive diagnostics into routine use, the role of multimodal data in better decision-making, and how BostonGene is working with pharma to design smarter trials from the outset. This is a practical conversation about precision oncology, multimodal diagnostics, AI in drug development, and turning complex biology into clinically useful decisions. Key takeaways: 🔹 Why single-gene and narrow-panel testing often misses the full picture in oncology 🔹 How BostonGene is combining genomics, transcriptomics, and immune profiling to improve treatment selection 🔹 Why reimbursement still lags behind the scientific need for integrated diagnostics 🔹 How multimodal AI and foundation models could reshape drug development and clinical trial design 🔹 What precision medicine companies need to understand about flexibility, regulation, and real-world adoption Chapters: 00:00 Introduction to Alexander Bagaev 03:25 Journey from physics to immunology 05:07 The evolution of BostonGene 07:55 Precision medicine and patient-centric treatment selection 10:28 Challenges in drug development and clinical trials 13:02 Growth and milestones of BostonGene 15:19 Navigating diagnostics and the role of AI 20:48 Future opportunities and advice for early-stage companies Guest: Alexander Bagaev Chief Product Officer at BostonGene LinkedIn: https://www.linkedin.com/in/alexander-bagaev-5548166b/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    Can AI Rescue Cancer Drugs That Clinical Trials Say Have Failed?

  5. 7月7日

    What If We Could Test Depression Drugs Before Patients Take Them? Dr Talia Cohen Solal - NeuroKaire

    In this episode of Diagnosing Dx, David Filby is joined by Talia Cohen Solal, CEO at NeuroKaire. Talia is a neuroscientist by training who spent more than a decade in academia, including time at Oxford, UCL, and Columbia, before moving into the startup world to get closer to real patient impact. In this conversation, we explore why precision medicine has transformed fields like oncology but still has so far to go in psychiatry, and how NeuroKaire is trying to change that. We discuss the limits of current antidepressant prescribing and how NeuroKaire is using patient-derived neurons to predict which treatments are most likely to work for each individual. This is a practical conversation about precision psychiatry, commercialization, clinical evidence, and what it takes to bring better mental health diagnostics into real patient care. Key takeaways: 🔹 Why psychiatry still lacks the precision medicine approach seen in other fields 🔹 How NeuroKaire is using patient-derived neurons to guide antidepressant treatment 🔹 Why clinical trials and guideline change are essential for real adoption 🔹 How the company is balancing commercial growth with platform expansion and pharma partnerships 🔹 What the future could look like for diagnostics in depression, anxiety, ADHD, and beyond Guest: Talia Cohen Solal CEO at NeuroKaire LinkedIn: https://www.linkedin.com/in/talia-cohen-solal-5b49a78/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ Chapters: 00:00 Introduction to Talia Cohen Solal and her background 08:23 Transitioning from academia to startups 09:52 The vision behind NeuroKaire and precision psychiatry 12:38 Clinical trials and validation of NeuroKaire’s technology 14:37 Commercialization, distribution, and reimbursement 16:46 Education and awareness in the medical community 19:44 Future growth, market potential, and new indications 26:47 Outlook on diagnostics and the future of neurodiagnostics 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    What If We Could Test Depression Drugs Before Patients Take Them? Dr Talia Cohen Solal - NeuroKaire

  6. 6月30日

    Why AI Multiomics Will Replace Ultrasound in Liver Cancer Screening with Bharat Tewarie

    In this episode of Diagnosing Dx, David Filby is joined by Bharat Tewarie, MD, MBA, CEO at Helio Genomics.   Bharat has led Helio Genomics since July 2025, bringing decades of global healthcare leadership across pharma, biotech, diagnostics, and digital health. In this conversation, we explore why liver cancer surveillance still relies too heavily on outdated imaging, why so many high-risk patients fall through the cracks, and how Helio Genomics is trying to change that with HelioLiver, its blood-based test designed to improve early detection.   We discuss the limitations of ultrasound in liver cancer screening, the promise of AI-powered multiomics, and why early detection only matters if patients can actually access it. Bharat also shares how his clinical and commercial background shapes Helio’s strategy, from workflow design and physician adoption to partnerships, awareness, and the infrastructure needed to move from scientific validation to real clinical impact.   This is a practical conversation about liver cancer, access, commercialization, and what it takes to turn better diagnostics into better outcomes.   Key takeaways:   🔹 Why liver cancer surveillance still leaves too many high-risk patients undetected 🔹 How AI-powered multiomics and HelioLiver could improve early liver cancer detection 🔹 Why access and workflow matter just as much as scientific performance 🔹 How partnerships can accelerate commercialization and patient reach 🔹 What Helio Genomics is building beyond HelioLiver as it expands its platform   Guest: Bharat Tewarie, MD, MBA CEO at Helio Genomics LinkedIn: https://www.linkedin.com/in/bharattewarie/   Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ Chapters: 00:00 Introduction to Bharat Tewarie and Helio Genomics 01:42 Bharat’s journey from medicine to business 06:25 The evolution of diagnostics, omics, and AI 10:36 Helio Genomics’ mission and differentiators 12:03 Unmet needs in liver cancer surveillance 14:01 Awareness, access, and clinical workflow challenges 19:10 The role of partnerships in commercialization 26:27 Growth strategy and the future of diagnostics   🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    Why AI Multiomics Will Replace Ultrasound in Liver Cancer Screening with Bharat Tewarie

  7. 6月17日

    Start with Reimbursement and Work Backwards - Jonathan Romanowsky

    In this episode of Diagnosing Dx, I’m joined by Jonathan Romanowsky, co-founder of Inflammatix and Principal at Kadima Spark.Jonathan shares lessons from leading diagnostics launches at CareDx, CardioDX, Veracyte, and Inflammatix. We discuss commercialization, reimbursement, fundraising, and why startups need to think about market adoption much earlier than before.We also explore Inflammatix’s evolution into a full IVD company and the key factors that separate diagnostics companies that launch from those that successfully scale.Key takeaways:🔹 Why reimbursement strategy needs to shape diagnostics planning from the start🔹 What makes a launch succeed beyond strong science and clinical validation🔹 Why early-stage companies now need commercial credibility much sooner🔹 How Inflammatix evolved from a molecular signature company into an IVD platform business🔹 What diagnostics founders need to understand about scale, systems, and adoption in 2026Chapters:01:28 Jonathan Romanowsky’s background and career in diagnostics06:20 Why he launched Kadima Spark and what companies need most today11:46 How fundraising pressure is changing commercial strategy22:00 The origin story of Inflammatix29:16 Building a platform company and preparing for launch33:23 Why some diagnostics launches succeed and others fail41:44 How early adoption really works inside health systems44:32 Jonathan’s outlook on the diagnostics market in 2026Guest: Jonathan RomanowskyMedical technology commercialization expert, co-founder of Inflammatix, and Principal at Kadima SparkLinkedIn: https://www.linkedin.com/in/jonathan-romanowsky-6a122/Host: David FilbyFounder and CEO of Elevra ConsultingLinkedIn: https://www.linkedin.com/in/davidfilby/🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.#Diagnostics #Commercialization #Inflammatix #MedicalTechnology #IVD #Biotech #HealthTech #Reimbursement #ProductMarketFit #Fundraising #GoToMarket #ClinicalAdoption #Veracyte #CareDx #DiagnosingDx

    Start with Reimbursement and Work Backwards - Jonathan Romanowsky

  8. 6月16日

    Start with Reimbursement and Work Backwards - Jonathan Romanowsky

    In this episode of Diagnosing Dx, I’m joined by Jonathan Romanowsky, co-founder of Inflammatix and Principal at Kadima Spark. Jonathan shares lessons from leading diagnostics launches at CareDx, CardioDx, Veracyte, and Inflammatix. We discuss commercialization, reimbursement, fundraising, and why startups need to think about market adoption much earlier than before. We also explore Inflammatix’s evolution into a full IVD company and the key factors that separate diagnostics companies that launch from those that successfully scale. Key takeaways: 🔹 Why reimbursement strategy needs to shape diagnostics planning from the start 🔹 What makes a launch succeed beyond strong science and clinical validation 🔹 Why early-stage companies now need commercial credibility much sooner 🔹 How Inflammatix evolved from a molecular signature company into an IVD platform business 🔹 What diagnostics founders need to understand about scale, systems, and adoption in 2026 Chapters: 01:28 Jonathan Romanowsky’s background and career in diagnostics 06:20 Why he launched Kadima Spark and what companies need most today 11:46 How fundraising pressure is changing commercial strategy 22:00 The origin story of Inflammatix 29:16 Building a platform company and preparing for launch 33:23 Why some diagnostics launches succeed and others fail 41:44 How early adoption really works inside health systems 44:32 Jonathan’s outlook on the diagnostics market in 2026 Guest: Jonathan Romanowsky Medical technology commercialization expert, co-founder of Inflammatix, and Principal at Kadima Spark LinkedIn: https://www.linkedin.com/in/jonathan-romanowsky-6a122/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    Start with Reimbursement and Work Backwards - Jonathan Romanowsky
顯示全部 (94)

簡介

How do we transform cutting-edge scientific discoveries into life-saving diagnostics? On Diagnosing Dx, we explore the scientific innovation driving diagnostics forward, unpack industry challenges, and spotlight success stories. Join us as we speak with leading researchers and innovators at the forefront of Dx. Learn to: 🔹 Navigate industry challenges 🔹 Understand emerging science 🔹 Strategise for growth 🔹 Gain future-focused insight Essential listening for everyone involved in bringing new sciences to life in the Dx and Omics industry, Subscribe now!

資訊

  • 創作者
    Elevra Consulting
  • 活躍年代
    2025年 - 2026年
  • 集數
    94
  • 年齡分級
    兒少適宜
  • 版權
    © 2026 Elevra Consulting
  • 節目網站
    Diagnosing Dx

你可能也會喜歡